NEUROTROPE is a clinical-stage biotech company leveraging Bryostatin-1 and its analogues to develop targeted therapeutics for neurodegenerative diseases and developmental disorders.  NEUROTROPE’s experience and passion for novel drug therapies have enabled it to develop a pipeline that includes various treatment approaches for serious and difficult-to-treat diseases such as Alzheimer’s Disease, Fragile X Syndrome and Niemann-Pick Type C.

The Company is currently in the middle of a Phase 2 confirmatory trial of Bryostatin-1 and advanced Alzheimer’s Disease.